Skip to main content
OpenTrials
Completed

NCT Number: NCT02896361

Burst Optimized Stimulation Study

This purpose of this study is to evaluate the therapeutic efficacy of burst microdosing stimulation paradigms in patients with chronic pain.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

NKO Sint-Augustinus, Antwerp, Belgium

Loading trial locations.

About this study

This is a prospective, multicenter, randomized, double-blinded crossover study designed to compare conventional burst stimulation parameters to two different burst microdosing paradigms.

Subjects will be randomized 1:1:1 to one of the three groups. Each group will evaluate all 3 stimulation paradigms in different order.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject has been implanted with a commercially available SJM spinal cord stimulator for controlling chronic intractable pain associated with back and/or leg pain;
  • Subject has been exclusively using burst stimulation for at least three months;
  • Subject is 18 years of age or older;
  • Subject's pain-related medication regimen was stable in the 4 weeks prior to the screening evaluation;
  • Subject agrees not to add or increase pain-related medication from enrollment through the study duration;
  • Subject is willing to cooperate with the study requirements including compliance with the regimen and completion of all office visits;

Exclusion criteria

  • Subject is currently participating in a clinical investigation study that includes an active treatment arm;
  • Subject is currently receiving, applying or considering seeking workers compensation, or is involved in disability litigation;
  • Subject has a non SJM neuromodulation device

Treatment and study plan

Reprogramming of spinal cord stimulator (Proclaim or Prodigy SJM internal pulse generator) parameters according to study protocol

Device

Stimulation parameters are reprogrammed from original values to study defined ones

Primary outcomes

  1. Visual Analog Scale (VAS) for Pain

    Time frame: assessed every 2 weeks after each intervention, for a total of 6 weeks

    Standard evaluation of pain intensity. Scale goes from 0 to 100 millimiters. 0 means no pain, 100 means strongest imaginable pain

Secondary outcomes

  1. EQ-5D

    Time frame: assessed every 2 weeks after each intervention, for a total of 6 weeks

    European Quality of life questionnaire 5 dimensions. Range goes from 0 to 1. 0 represents low quality of life, 1 represents high quality of life

  2. Subject Preference

    Time frame: assessed 6 weeks after baseline at the last follow up visit

    questionnaire to identify preferred stimulation paradigm. multiple choice questionnaire. Possible answers were

    • first intervention
    • second intervention
    • third intervention
    • no preference
  3. Subject Satisfaction

    Time frame: assessed every 2 weeks after each intervention, for a total of 6 weeks

    questionnaire on satisfaction with current therapy

  4. Percentage of Participants With Adverse Events

    Time frame: assessed over 6 weeks of study participation

Sponsors and collaborators

Lead sponsor

Abbott Medical Devices

Industry

Collaborators

  • Klinikum Duisburg GmbH
  • Medizinische Einrichtungen der Universität Düsseldorf
  • NKO Sint-Augustinus Antwerpen

Registry information

Acronym: BOSS

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Sep 12, 2016
Registry last updated
May 30, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.